EDP Sciences logo
Submit your paper
Search
Menu
All issues Volume 31 / No 2 (April 2026) Wuhan Univ. J. Nat. Sci., 31 2 (2026) 185-204 References
Open Access
Issue
Wuhan Univ. J. Nat. Sci.
Volume 31, Number 2, April 2026
Page(s) 185 - 204
DOI https://doi.org/10.1051/wujns/2026312185
Published online 13 May 2026
  1. Grani G, Lamartina L, Durante C, et al. Follicular thyroid cancer and Hürthle cell carcinoma: Challenges in diagnosis, treatment, and clinical management[J]. The Lancet Diabetes & Endocrinology, 2018, 6(6): 500-514. [Google Scholar]
  2. Lloyd R V, Osamura R Y, Klöppel G, et al. World Health Organization Classification of Tumours of Endocrine Organs[M]. Lyon: IARC Press, 2017. [Google Scholar]
  3. Baloch Z W, Asa S L, Barletta J A, et al. Overview of the 2022 WHO classification of thyroid neoplasms[J]. Endocrine Pathology, 2022, 33(1): 27-63. [Google Scholar]
  4. Haugen B R, Alexander E K, Bible K C, et al. 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer[J]. Thyroid, 2016, 26(1): 1-133. [Google Scholar]
  5. Jalaly J B, Baloch Z W. Hürthle-cell neoplasms of the thyroid: An algorithmic approach to pathologic diagnosis in light of molecular advances[J]. Seminars in Diagnostic Pathology, 2020, 37(5): 234-242. [Google Scholar]
  6. Doerfler W R, Nikitski A V, Morariu E M, et al. Molecular alterations in Hürthle cell nodules and preoperative cancer risk[J]. Endocrine-Related Cancer, 2021, 28(5): 301-309. [Google Scholar]
  7. Ganly I, Makarov V, Deraje S, et al. Integrated genomic analysis of Hürthle cell cancer reveals oncogenic drivers, recurrent mitochondrial mutations, and unique chromosomal landscapes[J]. Cancer Cell, 2018, 34(2): 256-270.e5. [Google Scholar]
  8. Ganly I, Filho J R, Eng S, et al. Genomic dissection of Hurthle cell carcinoma reveals a unique class of thyroid malignancy[J]. The Journal of Clinical Endocrinology and Metabolism, 2013, 98(5): E962-E972. [Google Scholar]
  9. Gopal R K, Kübler K, Calvo S E, et al. Widespread chromosomal losses and mitochondrial DNA alterations as genetic drivers in Hürthle cell carcinoma[J]. Cancer Cell, 2018, 34(2): 242-255.e5. [Google Scholar]
  10. Schatz-Siemers N, Brandler C T, Oweity T, et al. Hürthle cell lesions on thyroid fine needle aspiration cytology: Molecular and histologic correlation[J]. Diagnostic Cytopathology, 2019, 47(10): 977-985. [Google Scholar]
  11. Wong K S, Angell T E, Barletta J A, et al. Hürthle cell lesions of the thyroid: Progress made and challenges remaining[J]. Cancer Cytopathology, 2021, 129(5): 347-362. [Google Scholar]
  12. Evangelisti C, de Biase D, Kurelac I, et al. A mutation screening of oncogenes, tumor suppressor gene TP53 and nuclear encoded mitochondrial complex I genes in oncocytic thyroid tumors[J]. BMC Cancer, 2015, 15: 157. [Google Scholar]
  13. Kasaian K, Chindris A M, Wiseman S M, et al. MEN1 mutations in Hürthle cell (oncocytic) thyroid carcinoma[J]. J Clin Endocrinol Metab, 2015, 100(4): E611-E615. [Google Scholar]
  14. Landa I, Ibrahimpasic T, Boucai L, et al. Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers[J]. J Clin Invest, 2016, 126(3): 1052-1066. [Google Scholar]
  15. Nikiforova M N, Wald A I, Roy S, et al. Targeted next-generation sequencing panel (ThyroSeq) for detection of mutations in thyroid cancer[J]. J Clin Endocrinol Metab, 2013, 98(11): E1852-E1860. [Google Scholar]
  16. Wei S Z, LiVolsi V A, Montone K T, et al. PTEN and TP53 mutations in oncocytic follicular carcinoma[J]. Endocrine Pathology, 2015, 26(4): 365-369. [Google Scholar]
  17. McFadden D G, Sadow P M. Genetics, diagnosis, and management of Hürthle cell thyroid neoplasms[J]. Frontiers in Endocrinology, 2021, 12: 696386. [Google Scholar]
  18. Yeh J J, Lunetta K L, van Orsouw N J, et al. Somatic mitochondrial DNA (mtDNA) mutations in papillary thyroid carcinomas and differential mtDNA sequence variants in cases with thyroid tumours[J]. Oncogene, 2000, 19(16): 2060-2066. [Google Scholar]
  19. Bonora E, Porcelli A M, Gasparre G, et al. Defective oxidative phosphorylation in thyroid oncocytic carcinoma is associated with pathogenic mitochondrial DNA mutations affecting complexes I and Ⅲ[J]. Cancer Research, 2006, 66(12): 6087-6096. [Google Scholar]
  20. Gasparre G, Porcelli A M, Bonora E, et al. Disruptive mitochondrial DNA mutations in complex I subunits are markers of oncocytic phenotype in thyroid tumors[J]. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104(21): 9001-9006. [Google Scholar]
  21. Máximo V, Sobrinho-Simões M. Mitochondrial DNA 'common' deletion in Hürthle cell lesions of the thyroid[J]. The Journal of Pathology, 2000, 192(4): 561-562. [Google Scholar]
  22. Wredenberg A, Wibom R, Wilhelmsson H, et al. Increased mitochondrial mass in mitochondrial myopathy mice[J]. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99(23): 15066-15071. [Google Scholar]
  23. Goffredo P, Roman S A, Sosa J A. Hurthle cell carcinoma: A population-level analysis of 3311 patients[J]. Cancer, 2013, 119(3): 504-511. [Google Scholar]
  24. Chindris A M, Casler J D, Bernet V J, et al. Clinical and molecular features of Hürthle cell carcinoma of the thyroid[J]. The Journal of Clinical Endocrinology and Metabolism, 2015, 100(1): 55-62. [Google Scholar]
  25. Shaha A R, Shah J P, Loree T R. Patterns of nodal and distant metastasis based on histologic varieties in differentiated carcinoma of the thyroid[J]. The American Journal of Surgery, 1996, 172(6): 692-694. [Google Scholar]
  26. Haigh P I, Urbach D R. The treatment and prognosis of Hürthle cell follicular thyroid carcinoma compared with its non-Hürthle cell counterpart[J]. Surgery, 2005, 138(6): 1152-1158. [Google Scholar]
  27. Kushchayeva Y, Duh Q Y, Kebebew E, et al. Comparison of clinical characteristics at diagnosis and during follow-up in 118 patients with Hürthle cell or follicular thyroid cancer[J]. The American Journal of Surgery, 2008, 195(4): 457-462. [Google Scholar]
  28. Hundahl S A, Fleming I D, Fremgen A M, et al. A national cancer data base report on 53 856 cases of thyroid carcinoma treated in the U.S., 1985-1995[J]. Cancer, 1998, 83(12): 2638-2648. [Google Scholar]
  29. Ahmadi S, Stang M, Jiang X, et al. Hürthle cell carcinoma: Current perspectives[J]. OncoTargets and Therapy, 2016, 9: 6873-6884. [Google Scholar]
  30. Yutan E, Clark O H. Hürthle cell carcinoma[J]. Current Treatment Options in Oncology, 2001, 2(4): 331-335. [Google Scholar]
  31. Oluic B, Paunovic I, Loncar Z, et al. Survival and prognostic factors for survival, cancer specific survival and disease free interval in 239 patients with Hürthle cell carcinoma: A single center experience[J]. BMC Cancer, 2017, 17(1): 371. [Google Scholar]
  32. Petric R, Gazic B, Besic N. Prognostic factors for disease-specific survival in 108 patients with Hürthle cell thyroid carcinoma: A single-institution experience[J]. BMC Cancer, 2014, 14: 777. [Google Scholar]
  33. Mills S C, Haq M, Smellie W J B, et al. Hürthle cell carcinoma of the thyroid: Retrospective review of 62 patients treated at the royal marsden hospital between 1946 and 2003[J]. European Journal of Surgical Oncology, 2009, 35(3): 230-234. [Google Scholar]
  34. Ucal Y, Ozpinar A. Proteomics in thyroid cancer and other thyroid-related diseases: A review of the literature[J]. Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics, 2020, 1868(11): 140510. [Google Scholar]
  35. Shao W G, Guo T N, Toussaint N C, et al. Comparative analysis of mRNA and protein degradation in prostate tissues indicates high stability of proteins[J]. Nature Communications, 2019, 10(1): 2524. [Google Scholar]
  36. Jiang L H, Wang M, Lin S, et al. A quantitative proteome map of the human body[J]. Cell, 2020, 183(1): 269-283.e19. [Google Scholar]
  37. Sun Y T, Selvarajan S, Zang Z L, et al. Artificial intelligence defines protein-based classification of thyroid nodules[J]. Cell Discovery, 2022, 8(1): 85. [Google Scholar]
  38. Chen T, Ma J, Liu Y, et al. iProX in 2021: Connecting proteomics data sharing with big data[J]. Nucleic Acids Research, 2022, 50(D1): D1522-D1527. [Google Scholar]
  39. Consortium T U. UniProt: The universal protein knowledgebase[J]. Nucleic Acids Research, 2017, 45(D1): D158-D169. [Google Scholar]
  40. Shen W T, Song Z G, Zhong X, et al. Sangerbox: A comprehensive, interaction-friendly clinical bioinformatics analysis platform[J]. iMeta, 2022, 1(3): e36. [Google Scholar]
  41. Sherman B T, Hao M, Qiu J, et al. DAVID: A web server for functional enrichment analysis and functional annotation of gene lists (2021 update)[J]. Nucleic Acids Research, 2022, 50(W1): W216-W221. [Google Scholar]
  42. Szklarczyk D, Kirsch R, Koutrouli M, et al. The STRING database in 2023: Protein-protein association networks and functional enrichment analyses for any sequenced genome of interest[J]. Nucleic Acids Research, 2023, 51(D1): D638-D646. [Google Scholar]
  43. Shannon P, Markiel A, Ozier O, et al. Cytoscape: A software environment for integrated models of biomolecular interaction networks[J]. Genome Research, 2003, 13(11): 2498-2504. [Google Scholar]
  44. Zhou G Y, Soufan O, Ewald J, et al. NetworkAnalyst 3.0: A visual analytics platform for comprehensive gene expression profiling and meta-analysis[J]. Nucleic Acids Research, 2019, 47(W1): W234-W241. [Google Scholar]
  45. Davis C A, Hitz B C, Sloan C A, et al. The encyclopedia of DNA elements (ENCODE): Data portal update[J]. Nucleic Acids Research, 2018, 46(D1): D794-D801. [Google Scholar]
  46. Liu Z P, Wu C L, Miao H Y, et al. RegNetwork: An integrated database of transcriptional and post-transcriptional regulatory networks in human and mouse[J]. Database, 2015, 2015: bav095. [Google Scholar]
  47. Piñero J, Bravo À, Queralt-Rosinach N, et al. DisGeNET: A comprehensive platform integrating information on human disease-associated genes and variants[J]. Nucleic Acids Research, 2017, 45(D1): D833-D839. [Google Scholar]
  48. Wishart D S, Feunang Y D, Guo A C, et al. DrugBank 5.0: A major update to the DrugBank database for 2018[J]. Nucleic Acids Research, 2018, 46(D1): D1074-D1082. [Google Scholar]
  49. Yang X M, Wang X Q, Hu L P, et al. Nucleolar HEAT repeat containing 1 up-regulated by the mechanistic target of rapamycin complex 1 signaling promotes hepatocellular carcinoma growth by dominating ribosome biogenesis and proteome homeostasis[J]. Gastroenterology, 2023, 165(3): 629-646. [Google Scholar]
  50. Penzo M, Montanaro L, Treré D, et al. The ribosome biogenesis-cancer connection[J]. Cells, 2019, 8(1): 55. [Google Scholar]
  51. Narla A, Ebert B L. Ribosomopathies: Human disorders of ribosome dysfunction[J]. Blood, 2010, 115(16): 3196-3205. [Google Scholar]
  52. Stelzer G, Rosen N, Plaschkes I, et al. The GeneCards suite: From gene data mining to disease genome sequence analyses[J]. Current Protocols in Bioinformatics, 2016, 54(1): 1.30.1-1.30.33. [Google Scholar]
  53. Máximo V, Botelho T, Capela J, et al. Somatic and germline mutation in GRIM-19, a dual function gene involved in mitochondrial metabolism and cell death, is linked to mitochondrion-rich (Hürthle cell) tumours of the thyroid[J]. British Journal of Cancer, 2005, 92(10): 1892-1898. [Google Scholar]
  54. Chouhan S, Sawant M, Weimholt C, et al. TNK2/ACK1-mediated phosphorylation of ATP5F1A (ATP synthase F1 subunit alpha) selectively augments survival of prostate cancer while engendering mitochondrial vulnerability[J]. Autophagy, 2023, 19(3): 1000-1025. [Google Scholar]
  55. Sharma R K, Chafik A, Bertolin G. Aurora kinase A/AURKA functionally interacts with the mitochondrial ATP synthase to regulate energy metabolism and cell death[J]. Cell Death Discovery, 2023, 9(1): 203. [Google Scholar]
  56. Ba Y S, Ma F W, Ma Y W, et al. ATP5A1 participates in transcriptional and posttranscriptional regulation of cancer-associated genes by modulating their expression and alternative splicing profiles in HeLa cells[J]. Technology in Cancer Research & Treatment, 2021, 20: 15330338211039126. [Google Scholar]
  57. Yuan L S, Chen L, Qian K Y, et al. A novel correlation between ATP5A1 gene expression and progression of human clear cell renal cell carcinoma identified by co-expression analysis[J]. Oncology Reports, 2018, 39(2): 525-536. [Google Scholar]
  58. Repetto O, De Re V, Giuffrida P, et al. Proteomics signature of autoimmune atrophic gastritis: Towards a link with gastric cancer[J]. Gastric Cancer, 2021, 24(3): 666-679. [Google Scholar]
  59. Zhang G F, Zhong J M, Lin L, et al. Loss of ATP5A1 enhances proliferation and predicts poor prognosis of colon adenocarcinoma[J]. Pathology–Research and Practice, 2022, 230: 153679. [Google Scholar]
  60. Yue L Y, Liu P, Ma N T, et al. Interaction between extracellular ATP5A1 and LPS alleviates LPS-induced neuroinflammation in mice[J]. Neuroscience Letters, 2021, 758: 136005. [Google Scholar]
  61. Lines M A, Cuillerier A, Chakraborty P, et al. A recurrent de novo ATP5F1A substitution associated with neonatal complex V deficiency[J]. European Journal of Human Genetics, 2021, 29(11): 1719-1724. [Google Scholar]
  62. Nasca A, Mencacci N E, Invernizzi F, et al. Variants in ATP5F1B are associated with dominantly inherited dystonia[J]. Brain, 2023, 146(7): 2730-2738. [Google Scholar]
  63. Slater K, Bosch R, Smith K F, et al. 1, 4-dihydroxy quininib modulates the secretome of uveal melanoma tumour explants and a marker of oxidative phosphorylation in a metastatic xenograft model[J]. Frontiers in Medicine, 2023, 9: 1036322. [Google Scholar]
  64. Mahdevar M, Vatandoost J, Seyed Forootan F, et al. Steroid receptor RNA activator gene footprint in the progression and drug resistance of colorectal cancer through oxidative phosphorylation pathway[J]. Life Sciences, 2021, 285: 119950. [Google Scholar]
  65. Fiorillo M, Scatena C, Naccarato A G, et al. Bedaquiline, an FDA-approved drug, inhibits mitochondrial ATP production and metastasis in vivo, by targeting the gamma subunit (ATP5F1C) of the ATP synthase[J]. Cell Death and Differentiation, 2021, 28(9): 2797-2817. [Google Scholar]
  66. Song K H, Kim J H, Lee Y H, et al. Mitochondrial reprogramming via ATP5H loss promotes multimodal cancer therapy resistance[J]. The Journal of Clinical Investigation, 2018, 128(9): 4098-4114. [Google Scholar]
  67. Boada M, Antúnez C, Ramírez-Lorca R, et al. ATP5H/KCTD2 locus is associated with Alzheimer's disease risk[J]. Molecular Psychiatry, 2014, 19(6): 682-687. [Google Scholar]
  68. Zavileyskiy L, Bunik V. Regulation of p53 function by formation of non-nuclear heterologous protein complexes[J]. Biomolecules, 2022, 12(2): 327. [Google Scholar]
  69. Bottani E, Cerutti R, Harbour M E, et al. TTC19 plays a husbandry role on UQCRFS1 turnover in the biogenesis of mitochondrial respiratory complex Ⅲ[J]. Molecular Cell, 2017, 67(1): 96-105.e4. [Google Scholar]
  70. Yu J, Liang Q Y, Wang J, et al. Zinc-finger protein 331, a novel putative tumor suppressor, suppresses growth and invasiveness of gastric cancer[J]. Oncogene, 2013, 32(3): 307-317. [Google Scholar]
  71. Owens K M, Kulawiec M, Desouki M M, et al. Impaired OXPHOS complex Ⅲ in breast cancer[J]. PLoS One, 2011, 6(8): e23846. [Google Scholar]
  72. Natrajan R, MacKay A, Wilkerson P M, et al. Functional characterization of the 19q12 amplicon in grade Ⅲ breast cancers[J]. Breast Cancer Research, 2012, 14(2): R53. [Google Scholar]
  73. Becherini P, Caffa I, Piacente F, et al. SIRT6 enhances oxidative phosphorylation in breast cancer and promotes mammary tumorigenesis in mice[J]. Cancer & Metabolism, 2021, 9(1): 6. [Google Scholar]
  74. Nordlund J, Milani L, Lundmark A, et al. DNA methylation analysis of bone marrow cells at diagnosis of acute lymphoblastic leukemia and at remission[J]. PLoS One, 2012, 7(4): e34513. [Google Scholar]
  75. Jun K H, Kim S Y, Yoon J H, et al. Amplification of the UQCRFS1 gene in gastric cancers[J]. Journal of Gastric Cancer, 2012, 12(2): 73-80. [Google Scholar]
  76. Ellinger J, Gromes A, Poss M, et al. Systematic expression analysis of the mitochondrial complex Ⅲ subunits identifies UQCRC1 as biomarker in clear cell renal cell carcinoma[J]. Oncotarget, 2016, 7(52): 86490-86499. [Google Scholar]
  77. De Marco C, Zoppoli P, Rinaldo N, et al. Genome-wide analysis of copy number alterations led to the characterisation of PDCD10 as oncogene in ovarian cancer[J]. Translational Oncology, 2021, 14(3): 101013. [Google Scholar]
  78. Ha J H, Jayaraman M, Yan M D, et al. GNAi2/gip2-regulated transcriptome and its therapeutic significance in ovarian cancer[J]. Biomolecules, 2021, 11(8): 1211. [Google Scholar]
  79. Sun Q R, Li J Q, Dong H, et al. UQCRFS1 serves as a prognostic biomarker and promotes the progression of ovarian cancer[J]. Scientific Reports, 2023, 13(1): 8335. [Google Scholar]
  80. Bai H Y, Wang Y L, Liu H M, et al. Development of a four-mRNA expression-based prognostic signature for cutaneous melanoma[J]. Frontiers in Genetics, 2021, 12: 680617. [Google Scholar]
  81. Yusenko M V, Ruppert T, Kovacs G. Analysis of differentially expressed mitochondrial proteins in chromophobe renal cell carcinomas and renal oncocytomas by 2-D gel electrophoresis[J]. International Journal of Biological Sciences, 2010, 6(3): 213-224. [Google Scholar]
  82. Liu J P, Zhan X Q, Li M Y, et al. Mitochondrial proteomics of nasopharyngeal carcinoma metastasis[J]. BMC Medical Genomics, 2012, 5: 62. [Google Scholar]
  83. Zeng J, Li G L, Xia Y, et al. miR-204/COX5A axis contributes to invasion and chemotherapy resistance in estrogen receptor-positive breast cancers[J]. Cancer Letters, 2020, 492: 185-196. [Google Scholar]
  84. Jung S E, Kim S W, Jeong S, et al. MicroRNA-26a/b-5p promotes myocardial infarction-induced cell death by downregulating cytochrome c oxidase 5a[J]. Experimental & Molecular Medicine, 2021, 53(9): 1332-1343. [Google Scholar]
  85. Stanke K M, Wilson C, Kidambi S. High expression of glycolytic genes in clinical glioblastoma patients correlates with lower survival[J]. Frontiers in Molecular Biosciences, 2021, 8: 752404. [Google Scholar]
  86. Majercikova Z, Dibdiakova K, Gala M, et al. Different approaches for the profiling of cancer pathway-related genes in glioblastoma cells[J]. International Journal of Molecular Sciences, 2022, 23(18): 10883. [Google Scholar]
  87. Ganly I, Liu E M, Kuo F S, et al. Mitonuclear genotype remodels the metabolic and microenvironmental landscape of Hürthle cell carcinoma[J]. Science Advances, 2022, 8(25): eabn9699. [Google Scholar]
  88. Comelli M, Metelli G, Mavelli I. Downmodulation of mitochondrial F0F1 ATP synthase by diazoxide in cardiac myoblasts: A dual effect of the drug[J]. American Journal of Physiology Heart and Circulatory Physiology, 2007, 292(2): H820-H829. [Google Scholar]
  89. Ravindra K C, Ho W E, Cheng C, et al. Untargeted proteomics and systems-based mechanistic investigation of artesunate in human bronchial epithelial cells[J]. Chemical Research in Toxicology, 2015, 28(10): 1903-1913. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.